YiLinCloud Unveils IPO Prospectus: Pioneering AI-Driven Digital Transformation in Clinical Trials

Algorithms and models, as the lifeline of AI in pharmaceuticals, have long drawn significant industry attention to their ongoing transformation.

As large language models, powered by generative AI, sweep through the healthcare sector, new drug development is being reshaped by a new generation of AI, unlocking fresh potential. Since its launch earlier this year, DeepSeek has already attracted adoption by numerous healthcare companies.

In this transformation,Yilin Cloud (Ningbo) Technology Co., Ltd. (hereinafter referred to as “Yilin Cloud”), an industry-leading AI technology company,Continuously optimize its integrated clinical evidence support SaaS cloud platform,Successfully expanded AI capabilities across the entire product portfolio, including EDC, eCOA, and eTMF, establishing an AI-enabled solution that covers the full spectrum of clinical research.Breaking the Deadlock in the Digitalization and Intelligence of Clinical Trials.

Notably, Yilin Cloud has achieved significant results after integrating AI technology across its entire product portfolio. For instance, the EDC system, leveraging OCR and NLP technologies, has improved efficiency by 50% and accuracy by 25% compared to traditional models; the eTMF system has ensured a 94% archival accuracy rate and increased document organization efficiency by 20%. Similar achievements continue to emerge across other products.

Yi Lin Yun has not only solved the challenge of improving efficiency in clinical research; as the company further advances the deep integration of AI in this field, a new era of intelligent clinical research is also dawning.

From the perspective of current industry development, large AI models are accelerating the restructuring of drug R&D logic, breaking through the traditional “double ten” curse, and ushering in a golden decade of high-efficiency innovation for the industry. The application of AI technology in the pharmaceutical sector has also become an irreversible trend.

However, two major issues must still be resolved to truly realize the application of this technology.

First,AI still faces challenges in drug development and clinical applications, including data quality and diversity, model interpretability and trustworthiness, and continuous learning and updating of models;Second,During the clinical implementation phase, AI technology still needs to address challenges such as regulatory compliance, multi-party collaboration, and complex workflows, ultimately creating an intelligent solution that spans the entire clinical research process and forms a closed-loop ecosystem.

The reason why Yilin Cloud is able to break through the digitalization and intelligence of clinical trials lies inFrom its inception, the company recognized the value of AI and established a technical architecture and product suite spanning the entire clinical research process.

Since its founding in 2020, Yilinyun has chosen to leverage technological innovation and AI empowerment,Actively apply and develop this technology. The company, in its early stages,Established an AI Innovation Center and partnered with multinational corporations such as AstraZeneca and Microsoft.During the course of cooperation,Yi Lin Yun has consistently remained at the forefront of the industry, addressing pain points in AI adoption by starting with innovative business solutions to accelerate clinical trial processes.

Early explorations also laid the foundation for the company's product research, development, and application.

Currently,Yi Lin Yun provides an integrated, interoperable cloud platform for clinical trials, as well as solutions for the assessment of clinical trial endpoints across various therapeutic areas, including central nervous system disorders and ophthalmology., while collaboratively driving the comprehensive optimization of clinical research processes, alsoIntegrate AI technology comprehensively across the entire product portfolio, while simultaneously developing intelligent solutions that span the full lifecycle of clinical research.

How exactly should it be applied?

For example, in the collection of clinical trial participant information, Yilin Cloud employs deep database simulation technology to ensure robust protection of participant privacy. Additionally, leveraging AI-based associative prediction, the system provides automatic suggestions for data entry, thereby minimizing arbitrary input and effectively enhancing data accuracy and consistency.

Furthermore, leveraging Yilin Cloud’s proprietary OCR model and natural language processing technologies, the company has developed a system that identifies submitted examination reports, extracts data, and converts it into structured formats for import into Electronic Data Capture (EDC) systems. This innovation significantly alleviates the burden of EDC data entry, delivering greater value particularly for large-scale, cost-effective data entry tasks.

Furthermore, Yilin Cloud leverages AI technology to establish intelligent early-warning rules and a multi-dimensional, bidirectional alert mechanism within its system, enabling users to conduct proactive data quality control. Meanwhile, AI technology supports the entire workflow of data quality management, achieving intelligent functional operations. With the aid of AI, the system can flexibly present data, monitor data changes in real time, and intelligently generate reports, ensuring that every stage—from patient data collection to trial result analysis—meets rigorous standards of precision and efficiency.

Yi Lin Yun’s strategic layout and technological applications further underscore the company’s differentiated competitive advantages—Build on the data-driven platform, integrate AI technologies, and deeply embed them into application scenarios.

Although the technology is already in place, how to implement large language models in practical applications has been a vexing issue from the very beginning.

Yi Lin Yun believes that although everyone now recognizes the value of AI, there are actually few partners who both possess a deep understanding of new drug development and are proficient in AI technology. At this stage, both pharmaceutical companies and CROs clearly hope to findPartners who understand both clinical research and AI technology, working together to bring the company’s ideas to fruition.

I. The early stage of Lin Yun'sIn addition to technical prowess, what matters more for collaborating with international companies is the team’s in-depth understanding of the business scenarios in biopharmaceutical clinical R&D.It is the combination of these two elements that constitutes an important cornerstone of cooperation. This has also laid the foundation for Yilin Cloud’s current and future development.

Throughout the process, Yilinyun has consistently promoted AI applications in a comprehensive and multi-dimensional manner.

In terms of product empowerment,Yi Lin Yun leverages AI technology to enable customers to experience the convenience of intelligence while using its products, while also addressing various issues;

In terms of expanding application dimensions,Yilin Cloud is not satisfied with the intelligence of its products alone; it also works closely with clients to integrate AI technology throughout the entire drug R&D process, and even jointly explores innovations with clients at critical stages.

In terms of corporate elevation dimensions,Yi Lin Yun deeply integrates AI technology into various job roles, including R&D, pre-sales and after-sales support, and business operations, to comprehensively enhance work efficiency.

Leveraging its early strategic layout and practical experience, Yilin Cloud has successfully established partnerships with numerous enterprises both domestically and internationally. Consequently, the company’s product positioning, product portfolio, team structure, and business strategy all adhere to a global perspective. From the outset of design, its products and product systems have strictly followed international standards, ensuring compliance with regulatory requirements worldwide. Furthermore, the company has extensively conducted overseas clinical trials.

Amid economic downturn and intense market competition, Yilin Cloud possesses not only technological advantages. Leveraging its AI-based applications, the company also holds certain advantages in the pace of technological iteration, the speed of application promotion, and the implementation cycle.

However, this is only the beginning.

In the clinical application phase, AI adoption is still in its infancy, having just begun to show its potential. In the future, AI will have numerous practical application scenarios in the clinical drug trial phase.

It is reported that a growing number of clients have begun engaging with Yilin Cloud to address their pain points and seek collaborative partnerships to co-create AI application solutions and specific use cases. This clearly demonstrates the urgent desire across the industry to keep pace with the AI era and ensure they are not left behind.

To this end, Yilinyun will continue to explore the potential value of technology, collaborate with key industry partners, and jointly develop a series of practical AI solutions. By integrating partners’ business needs and existing data assets, we aim to drive beneficial transformations across the entire clinical research workflow, maximize industry efficiency, and accelerate the new drug development process.